02:07 PM EDT, 06/03/2024 (MT Newswires) -- Optimi Health ( OPTHF ) , a licensed psychedelics pharmaceutical manufacturer specializing in controlled substances, was last seen up 12% after the company on Monday said Health Canada awarded the company a Drug Establishment Licence to manufacture and sell its MDMA and psilocybin capsules.

The designation affirmed a compliant rating for Good Manufacturing Practices. Optimi can now supply MDMA and psilocybin capsules to patients with post-traumatic stress disorder (PTSD) and Treatment-Resistant Depression under Australia's Authorised Prescriber Scheme and regulated jurisdictions globally pending export documentation from Health Canada.

The company will now work to register both drugs with the US Food and Drug Administration by implementing mutual recognition agreements.

Optimi shares were last seen up $0.50 to $0.48 on the Canadian Securities Exchange.

Price: 0.48, Change: +0.05, Percent Change: +11.63